The Zhuhai Hengqin mega-resort is recognised for its multiple theme parks, luxury hotels, exhibition spaces, shopping malls ...
Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...
The city’s annual green expo, the Macau International Environmental Co-operation Forum & Exhibition (MIECF), is showcasing 21 new products and solutions from regional entities this year, underlining ...
Leonel Alves, a Macau deputy to the central government’s top advisory body, has called for closer judicial cooperation ...
The United Laboratories, Novo Nordisk ink exclusive global license agreement for UBT251: Guangdong, China Wednesday, March 26, 2025, 10:00 Hrs [IST] The United Laboratories Intern ...
Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...
The United Laboratories International Holdings Limited and Novo Nordisk (NVO) announced earlier that Novo Nordisk and TUL’s wholly-owned ...
The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) ...
Stocktwits on MSN6d
Novo Nordisk Signs $2B Deal For Obesity Drug With Chinese Biotech: Retail Sentiment ImprovesDrugmaker Novo Nordisk A/S (NVO) on Monday entered into an exclusive license agreement worth up to $2 billion with ...
The business-software group claimed the top spot as Europe’s largest company by market value, dethroning Wegovy maker Novo ...
Co., Ltd. have entered into an exclusive license agreement for UBT251 for the treatment of obesity, type 2 diabetes, and other diseases.
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback